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Abstract  
The ontogenic relationship between the common dendritic cell (DC) progenitor, the 
committed conventional DC precursor (pre-cDC) and cDC subpopulations in 
lymphoid and non-lymphoid tissues have been largely unraveled. In contrast, the 
sequential steps of plasmacytoid DC (pDC) development are less defined and it is 
unknown at which developmental stage and location final commitment to the pDC 
lineage occurs. Here we show that CCR9- pDCs from murine bone marrow which 
enter the circulation and peripheral tissues have a common DC precursor function in 
vivo in the steady state in contrast to CCR9+ pDCs which are terminally 
differentiated. Upon adoptive transfer the fate of CCR9- pDC-like precursors is 
governed by the tissues they enter. In the bone marrow and liver most transferred 
CCR9- pDC-like precursors differentiate into CCR9+ pDCs, whereas in peripheral 
lymphoid organs, lung and intestine they additionally give rise to cDCs. CCR9- pDC-
like precursors which are distinct from pre-cDCs can be generated from the CDP. 
Thus, CCR9- pDC-like cells are novel CDP-derived circulating DC precursors with 
pDC and cDC potential. Their final differentiation into functionally distinct pDCs and 
cDCs depends on tissue-specific factors allowing adaptation to local requirements 
under homeostatic conditions. 
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Introduction 
Dendritic cells (DCs) are essential initiators of immunity and link innate to adaptive 
antimicrobial immune responses. DCs are also critically involved in maintaining 
immune tolerance against self antigens and harmless environmental antigens to 
prevent autoimmune and inflammatory reactions 1. Murine DCs found in lymphoid 
and non-lymphoid tissues in the steady state can be broadly classfied into tissue-
resident conventional or classical DCs (cDCs) and plasmacytoid DCs (pDCs). DCs 
residing in non-lymphoid tissues are also called migratory DCs due to their ability to 
migrate and carry antigens derived from the tissues to lymph nodes via lymphatics. 
CDC subpopulations residing in the spleen and lymph nodes comprise two major 
functionally distinct subpopulations, the CD8α+ CD11b- cDCs which are efficient in 
crosspresenting antigens to CD8+ T cells and the CD8α- CD11b+ cDCs which are 
potent stimulators of T helper cell responses 1. Likewise, two major distinct 
subpopulations can be found in non-lymphoid tissues, namely CD103+ and CD11b+ 
cDCs 2,3. CD103+ CD11b- cDCs in non-lymphoid tissues, such as skin, lung and 
intestine are functional equivalents of CD8α+ CD11b- splenic cDCs 4-7, while the 
relationship of non-lymphoid tissue CD11b+ DCs to CD8α- CD11b+ cDCs remains 
unclear.  
 
PDCs are found in bone marrow (BM) and blood as well as in peripheral lymphoid 
and non-lymphoid organs. Interestingly the frequency of pDCs among all CD11c+ 
DCs is high in the BM and in the liver, but much lower in spleen, lymph nodes and 
other organs. PDCs are functionally characterized by producing high amounts of type 
I interferons (IFNs) in response to viruses, which they sense via Toll-like receptors 7 
and 9 8. There is evidence that in addition to their role in secreting IFNs and 
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inflammatory cytokines, pDCs can function as antigen presenting cells 9. Depending 
on their localization, activation state and mechanism of antigen internalization pDCs 
can induce protective adaptive immunity or immune tolerance 10-12. PDCs in the liver 
for example play a central role for induction of tolerance to orally administered 
antigens 13. 
 
Recent studies have worked out distinct developmental stages of DCs during their 
development from hematopoietic progenitors to fully differentiated DCs. A common 
DC progenitor (CDP) has been found in murine BM, which is restricted to DC 
development and gives rise to cDCs as well as pDCs 14,15. The CDP was shown to 
generate a cDC-committed precursor (pre-cDC), which circulates in the blood and 
can migrate to peripheral lymphoid and non-lymphoid organs where it gives rise to 
cDC subpopulations 6,16-18. The current model for pDC development says that pDCs 
arise from CDPs and are fully differentiated in the BM before they enter the blood 
stream and then migrate to peripheral tissues. The existence of a pDC-biased or 
pDC-committed precursor which can exit the BM and differentiate locally in the 
steady state has so far not been demonstrated.   
 
We have recently identified a potential candidate pDC precursor in murine BM 
expressing CD11c and pDC-specific surface molecules BST2 and Siglec-H but 
lacking or expressing low levels of CCR9 and low levels of MHCII in contrast to 
differentiated pDCs, which are CCR9+ and express higher levels of MHCII 19. This 
population expresses transcription factor E2-2 which drives pDC lineage 
differentiation and produces large amounts of type I IFN in response to TLR9 
stimulation demonstrating affiliation to the pDC lineage. While these CCR9- BM pDCs 
spontaneously differentiate into CCR9+ pDCs , they also give rise to cDC-like cells 
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after exposure to intestinal epithelial cell derived factors or recombinant GM-CSF in 
vitro. This diversion form the pDC lineage is accompanied by downregulation of E2-2 
and upregulation of transcription factors involved in cDC development, such as Id2 19.  
 
Here we show that these CCR9- pDC-like cells from murine BM are CDP-derived 
migratory common DC precursors with a bias to generate pDCs but with a significant 
potential to contribute to the cDC pool in vivo in the steady state. Final differentiation 
of these pDC-like precursors depends on the tissue microenvironment thus allowing 
adaptation of DC subset composition to the local requirements of different organs. 
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Materials and Methods 
Mice 
Specific pathogen free, female 6-8 week old C57BL/6 mice (CD45.2) were purchased 
from Harlan Winkelmann (Borchen, Germany). CX3CR1-eGFP reporter mice 20, 
Fucci transgenic mice 21, CSF2rb-/- mice 22, CD45.1 mice (C57BL/6 background) were 
bred under SPF conditions. Experiments were performed in accordance with German 
animal care and ethics legislation and have been approved by the local government 
authorities.  
 
Expansion of dendritic cells in vivo 
Dendritic cells were expanded by implantation of 5 x 106 cells of B16 Flt3L secreting 
melanoma cell line 23 subcutaneously in the neck of 6-8 week old mice for 7 days. 
 
Cell culture 
B16 Flt3L secreting melanoma cells were cultured prior to implantation for 3 days in 
RPMI 1640, 10% FCS, 1% Glutamax, 1% non-essential AA, 1% sodium pyruvate, 
1% Penicillin/Streptomycin (all Life technologies, Carlsbad, USA) in a humidified 
incubator at 37°C and 5% CO2. 
 
Primary cell isolation 
Blood was collected by heart puncture, spun down and red blood cells were lysed 
before analysis. BM cells were flushed out of femura and tibiae of the mice and 
single cell suspension was prepared by vigorous pipetting. Mice were carefully 
perfused with ice-cold PBS before excision of tissues. Spleen (Spl), Peyer’s patches 
(PP), mesenteric and inguinal lymph nodes (LN) and lung (Lg) were digested with 
collagenase D (500 µg/ml, Roche, Mannheim, Germany) and DNase I (100 µg/ml, 
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Roche). Liver (Li) was digested with DNase I and collagenase IV (500 µg/ml, Roche) 
and lymphocytes were enriched by Percoll gradient centrifugation (40% Percoll 
(Sigma-Aldrich), 2000 rpm, room temperature). Small intestinal (SI) and colonic 
leucocyte preparations (combined lamina propria and intraepithelial leucocytes) were 
prepared as described 24. Red blood cell lysis was performed on spleen, BM, lung 
and liver cells. Single cell suspensions from these organs and from BM were stained 
with the indicated fluorescently labeled antibodies and analysed by flow cytometry or 
sorted. 
 
Primary cell sorting 
CCR9- pDC-like precursors or CCR9+ pDCs were sorted from the BM of Flt3L 
expanded mice by gating on Siglec-Hhigh BST2high CD11cint cells and discriminating 
them by CCR9-/low and CCR9high expression. CDPs were sorted as Lin- (CD19, B220, 
CD3, NK1.1), MHC class II-, CD11c-, CD135+, CD115+, CD117-/low from BM cells of 
untreated mice which had been enriched for CD135+ cells using MACS technology 
(αCD135-bio, (eBioscience, San Diego, USA), αbio-beads, (Miltenyi, Bergisch-
Gladbach, Germany)). FACS sorting was performed on a MoFlow cell sorter 
(Beckman Coulter, Brea, USA). 
 
CDP in vitro culture 
CDPs were sorted as described above and 7 x 104 CD45.2+ CDPs were cocultured 
together with 4.5 x 106 CD45.1+ feeder BM cells in a 6 well plate for 4 days in DC 
medium (RPMI (Promocell, Heidelberg, Germany), 10% FCS, 1% Glutamax, 1% 
non-essential AA, 1% sodium pyruvate, 1% Penicillin/Streptomycin (all Life 
technologies), 50 µM β-mercaptoethanol (Sigma-Aldrich, St. Louis, USA) 
supplemented with 20 ng/ml rhFlt3L (prepared in our laboratory). 
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Morphological analysis 
For morphological analysis CCR9- pDC-like precursors and CCR9+ pDCs were 
sorted as described and cytospins were prepared. Diff-Quick stain (Medion 
Diagnostics, Düdingen, Switzerland) was performed and microscopy slides were 
assessed and images were captured using a Imager MR2 microscope and Axio cam 
Mrc 5 (both Zeiss, Jena, Germany) 100x magnification oil immersion objective. 
Images were processed using AxioVision software (Zeiss) and Photoshop CS4 
(Adobe Systems, San Jose, USA).  
 
Determination of proliferation 
Proliferation was assessed using the Fucci-transgenic mouse strain expressing the 
green fluorescent cell cycle indicator dye mAG-hGeminin which allows assessment 
of proliferation in vivo (Sakaue-Sawano A et al. Cell 2008). 
 
Adoptive transfer of pDCs and precursors 
To track CCR9- pDC-like precursors or CCR9+ pDCs in vivo up to 48h cells were 
labeled with 5 µM of Violet trace cell dye (Invitrogen, Karlsruhe, Germany) for 20 min 
at 37°C and washed twice with PBS supplemented with 5% FCS. 5 x 105 cells were 
injected i.v. into the tail vein of unirradiated steady state mice. Detection of 
transferred cells was not affected at this time point because only a low percentage of 
cells diluted the dye and these cells underwent only 1-2 division within 48 h. For 
analysis at later time points after transfer 5 x 105 CCR9- pDC-like cells were purified 
from CD45.2+ mice and injected into the tail veins of CD45.1+ congenic unirradiated 
mice and analysed 7 days later. CD45.2+ CDPs were sorted as described above and 
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1 x 105 CDPs were injected into the tail veins of CD45.1+ congenic unirradiated mice 
and analysed 5 or 7 days later. 
 
Flow cytometry  
For FACS analysis cells were stained using fluorescently labeled antibodies directed 
against the indicated cell surface antigens (CCR9-PE/APC, CD11c-PeCy7, CD11b-
PeCy5.5, MHCII-APC-eFluor780/eFluor450, CD103-PE/APC, CD8α-APC-
eFluor780/eFluor450, eBioscience) as described. Anti-BST2 (120G8, rat IgG1) 25 and 
anti-Siglec-H antibodies (440c, rat IgG2b) 26 were conjugated with FITC or Alexa 647. 
Propidium iodide (PI) was added to exclude dead cells from analysis. Cells were 
acquired using a Gallios flow cytometer (Beckman Coulter).  
 
Gene expression analysis 
CCR9+ pDCs and CCR9- pDC-like precursors were isolated from BM of 
unmanipulated C57BL/6 mice (6-8 weeks old) as described above. RNA was 
extracted with Ambion mirVana miRNA isolation kit (Life technologies, Carlsbad, 
USA). For each sample, 50 ng of total RNA was labeled with the TargetAmp™-Nano 
Labeling Kit for Illumina® Expression BeadChip (Epicentre Biotechnologies, 
Madison, WI, USA) and hybridized onto Mouse WG-6 v2 Beadchips (Illumina Inc., 
San Diego, CA, USA). Arrays were scanned with a BeadArray Scanner 500GX 
(Illumina Inc.). Chip images were analyzed using GenomeStudio Gene Expression v 
1.8.0 (Illumina Inc.). Data were Loess normalized, only probes with at least one 
significant detection value were included in the analysis. Multiple probes of genes 
were collapsed to the probe with the highest average expression value. Three 
independent microarray experiments were performed for each population (three 
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separate isolations of the two populations from three individual mice, six 
microarrays). 
 
DC and DC progenitor gene sets 
To build DC and DC progenitor gene sets, we used arrays from the ImmGen project 
(accessed at GEO, Series GSE15907. GSM791114-6 were used as CDP, 
GSM791105-7 as MDP, GSM538248-51/GSM538258-61/GSM538265-
7/GSM605826-7/GSM605837-9 as cDC, GSM605840-5 as pDC). CEL files were 
RMA-normalized using Expression Console software (Version 1.1, Affymetrix Inc.). 
Gene sets specific for each cell type were extracted using GenePattern analysis 
platform (Broad Institute of MIT and Harvard). In brief, DC array data were 
preprocessed using the platform's default parameters (PreprocessDataset module). 
Then, the ComparativeMarkerSelection module and 
ExtractComparativeMarkerResults module was used. For each cell type, the 200 
most specific genes were extracted. Out of these, all upregulated genes were used 
for comparison with our own gene expression data. 
 
Statistical Analysis 
Unpaired, two tailed Student’s t test was used to determine statistically significant 
differences (* p < 0.05, ** p < 0.01). 
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Results 
CCR9- but not CCR9+ murine bone marrow pDCs show a DC progenitor gene 
expression signature  
We have previously shown that although the phenotype and secretory function of 
CCR9- and CCR9+ pDCs are very similar, only the CCR9- population is flexible to 
divert from the pDC lineage and generate cDC-like cells in vitro 19. We therefore 
searched for differentially expressed genes between these two populations to explain 
this difference. The genome-wide expression profile of CCR9+ and CCR9- CD11c+ 
BST2+ Siglec-H+ cells freshly isolated from murine BM of unmanipulated C57BL/6 
mice was compared. As shown in figure 1a, 379 genes were expressed >2-fold 
higher in CCR9+ than in CCR9- BM pDCs (3.4 %) and 258 genes were expressed >2-
fold higher in CCR9- than in CCR9+ BM pDCs (2.3 %). The genes encoding major 
transcription factors driving pDC lineage differentiation, such as Tcf4 (E2-2) and Spib 
27,28
 as well as genes encoding pDC-specific cell surface molecules Siglec-H 29 and 
Bst2 30 showed less than 2-fold differences in expression between the two 
populations. Pairwise comparison confirmed the higher expression of CD8α, Ly6a 
(Sca-1), CXCR3, CD86 and CIITA (class II MHC transactivator) in CCR9+ than 
CCR9- BM pDCs as expected from our previous phenotypic analysis 19. Annotation of 
the differentially expressed genes showed that genes involved in DC function were 
preferentially expressed in CCR9+ pDCs (supplemental table 1), while genes 
involved in cell cycle events and indicated in cell development were overrepresented 
in the CCR9- population (supplemental table 2).  
 
Datasets from the ImmGen database 31 were used to generate expression signatures 
of CDPs, MDPs, splenic cDCs and splenic pDCs. Expression of these signature 
genes in CCR9+ and CCR9- BM pDCs was compared revealing that 35 DC 
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progenitor signature genes are expressed at higher levels in the CCR9- than in the 
CCR9+ population (figure 1b). MDP signature genes are similarly overrepresented in 
the CCR9- BM pDCs (supplemental figure S1a). In contrast, 36 splenic pDC 
signature genes are expressed at higher levels in the CCR9+ than the CCR9- BM 
pDCs including for example Tlr7, Ly6a (Sca-1), Klra17 (Ly-49Q), Sla2 and Pacsin1 
(figure 1d) although many known splenic pDC signature genes 27,32,33 are expressed 
at similar levels in the two populations, such as Tcf4, SpiB, Siglec-H, Bst2, Il7r, 
Atp1b1, Blnk and Runx2 (see figure 1a). Comparison with the signatures genes 
common to all cDC subpopulations showed that these were similarly expressed in 
both populations with few exceptions (see supplemental figure S1b). Thus, global 
gene expression analysis revealed that CCR9- pDC-like cells share gene expression 
patterns of both DC progenitors and pDCs. However, pDCs and pDC-like precursors 
coexpressing CD11c, BST2 and Siglec-H are distinct from CDPs which lack CD11c 
expression 15 and they are Lineage+ and MHCII+ in contrast to pre-cDCs as defined 
by Liu. et al 17 (supplemental figure 2a). Hence, there is no relevant overlap of CCR9- 
pDC-like precursors with CDPs and pre-cDCs. 
 
To validate the higher proliferative activity of CCR9- versus CCR9+ pDCs as indicated 
by our gene array data, the fluorescent, ubiquitination-based cell cycle indicator 
(Fucci) transgenic mouse was used, which expresses a green-fluorescent cell cycle 
indicator mAG-hGeminin accumulating in S/G2/M phases of the cell cycle 21. In the 
BM, the proliferative capacity of CCR9- pDC-like cells was higher than that of CCR9+ 
pDCs consistent with DC precursor function (figure 2a, left panels). In the spleen, the 
relative numbers of CCR9- pDC-like precursors in cell cycle was much lower than in 
the BM (figure 2a, right panels). Cytospin preparations of cells sorted from the BM 
showed that CCR9- pDC-like precursors are bigger cells with a more irregular 
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indented nucleus resembling CDPs and pre-cDCs by morphology 15,18. In contrast, 
CCR9+ BM pDCs are smaller and have the classical plasmacytoid morphology with a 
round shape and an excentric nucleus (figure 2b). Thus, although CCR9- pDC-like 
precursors phenotypically and functionally largely overlap with CCR9+ differentiated 
pDCs, they share the gene expression profile, proliferative capacity and morphology 
of DC progenitor or precursor cells.  
 
CCR9- pDC-like precursors migrate to peripheral organs  
CDC committed precursors (pre-cDCs) were found to migrate from the BM to 
peripheral lymphoid and non-lymphoid organs, where they further develop into cDC 
subpopulations 6,17. We hypothesized that CCR9- pDC-like precursors might be 
present in the blood and in peripheral tissues. BM, liver and blood contained the 
highest numbers of pDCs expressing CD11c, BST2 and Siglec-H, whereas pDCs 
were less frequent in peripheral organs (figure 3a). The relative numbers of cells 
lacking or expressing low levels of CCR9 among the CD11c+ BST2+ Siglec-H+ pDCs 
was highest in BM and liver, where the frequency of total pDCs is also high (figure 
3b). Substantial numbers of CCR9- pDC-like cells can be found in BM (0.51%), blood 
(0.01%), spleen (0.007%), lymph nodes (0.01%), Peyer’s patches (0.02%), as well as 
liver (0.09%), lung (0.005%), small intestine (0.02%) and colon (0.001%) among all 
leucocytes (figure 3c). Thus, CCR9- pDC-like precursors circulate in the blood and 
reside at least temporarily in peripheral tissues comparable to previously identified 
tissues resident cDC committed precursors.  
 
To investigate the homing capacity and developmental fate of CCR9- pDC-like 
precursors in vivo in comparison to CCR9+ differentiated pDCs, adoptive transfer 
experiments were performed using cells sorted from BM of C57BL/6 mice which had 
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been exposed to Flt3L for 7 days. Flt3L-mediated expansion increased the 
percentage of CD11c+ BST2+ Siglec-H+ pDCs in the BM from 3.2 ± 0.4 to 9.8% ± 
2.5% (mean ± SD) of all leucocytes, but did not alter the frequency of the CCR9- 
subset within this population (14.7% ± 3.2% versus 12.1% ± 3.2%). The phenotype of 
CCR9+ and CCR9- pDCs sorted from the BM of Flt3L exposed mice was comparable 
to that of cells analysed directly from BM of unmanipulated mice (supplemental figure 
2b and 19). 
 
Sorted cells were labeled with a Violet dye for their in vivo tracking and adoptively 
transferred into unmanipulated hosts. Both populations were found in the BM and 
peripheral lymphoid organs already 12 hours after intravenous injection (data not 
shown). The percentage of transferred Violet trace+ cells further increased after 24 
and 48 hours in peripheral lymphoid organs but remained stable in the BM (data not 
shown). Accumulation of transferred CCR9- pDC-like precursors was comparable to 
that of CCR9+ pDCs at the 48 hour time point in BM, spleen, lymph nodes, liver and 
small intestine, although a trend towards higher numbers of CCR9- pDC-like cells 
was observed in these organs (figure 3d-f). In lung, Peyer’s patches and colon, a 
significantly higher frequency of transferred CCR9- pDC-like cells than CCR9+ pDCs 
was found. These results show that both CCR9- pDC-like precursors and CCR9+ 
pDCs are recruited to peripheral lymphoid and non-lymphoid organs and accumulate 
there. Taken together we provide evidence that CCR9- pDC-like precursors can 
migrate to peripheral organs opening the possibility for their final differentiation to 
occur locally in tissues. 
 
Transferred CCR9- pDC-like cells rapidly acquire a cDC-like phenotype in 
secondary lymphoid and mucosal tissues 
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We had shown previously that in vitro CCR9- MHCIIlow pDC-like cells spontaneously 
differentiate into CCR9+ MHCII+ pDC, but can rapidly give rise to cDC-like cells in 
response to GMCSF, which is produced mainly under inflammatory conditions 34. Our 
hypothesis was therefore that CCR9- pDC-like precursors would be committed to 
differentiate into pDCs in vivo in the steady state. Transferred CCR9- pDC-like 
precursors found in BM and liver after 48 hours largely maintained their pDC 
phenotype reflected in high level expression of BST2 and Siglec-H (see figure 4a-b 
and 5) similar to transferred CCR9+ pDCs. Further phenotypic analysis (figure 5) 
showed that BST2high cells derived from CCR9- pDC-like precursors after 48 hours in 
spleen, lymph nodes and Peyer’s patches maintained high Siglec-H and low CD11b 
expression, but upregulated CCR9 and MHC class II consistent with the phenotype 
of fully differentiated pDCs.  
 
However, in contrast to CCR9+ pDCs, a significant percentage of transferred CCR9- 
pDC-like cells found in spleen, lymph nodes and Peyer’s patches had already 
downregulated BST2 at this time point and a similar trend was seen in lung and small 
intestine (figure 4a and b). Cell numbers in the colon were too small for reliable 
analysis. Interestingly, BST2low cells derived from these CCR9- precursors had 
downregulated Siglec-H while maintaining low CCR9 expression and had additionally 
upregulated MHC class II and CD11b consistent with a cDC-like phenotype (figure 
5). Thus, CCR9- pDC-like precursors have the potential to rapidly generate both 
pDCs and cDC-like cells in the steady state depending on the tissue environment. In 
addition, the pDC and cDC developmental potential of CCR9- pDC-like precursors 
lacking expression of the GMCSF receptor common β chain 22 was comparable to 
that of WT cells in BM, spleen, lymph nodes and Peyer’s patches (figure S3). Thus, 
GMCSF receptor signaling is not required for differentiation of these precursors into 
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cDC-like cells in the steady state in vivo, suggesting the additional involvement of 
other tissue-specific factors. 
 
pDC and cDC subtype differentiation potential of CCR9- pDC-like precursors in 
vivo is tissue-dependent  
Phenotypic analysis 48 hours after adoptive transfer of CCR9- pDC-like precursors 
demonstrated that these precursors can not only rapidly generate pDCs but also 
some cDC-like cells in lymphoid and non-lymphoid organs in the steady state. To 
investigate their potential to differentiate fully into cDC subpopulations at later time 
points, CCR9- pDC-like precursors (CD45.2) were transferred into CD45.1 recipients 
and their phenotype was analyzed 7 days after transfer. In BM and liver descendants 
of CCR9- pDC-like precursors were still predominantly pDCs, while in spleen and 
lung more cDCs than pDCs were derived from the transferred precursors at this time 
point (figure 6a and b). Among the cDCs derived from transferred CCR9- pDC-like 
precursors CD8α+ CD11b- and CD8α- CD11b+ cDCs were found in the spleen, while 
only CD11b+ CD103- cDCs were found in the lung (figure 6c).  
 
CDP give rise to CCR9- pDC-like precursors in vitro and in vivo 
The common DC progenitor (CDP) gives rise to both cDCs and pDCs. However, it is 
not proven that all pDCs are derived from CDPs. We therefore asked the question if 
CCR9- pDC-like precursors can be derived from CDPs. CDPs sorted as Lin- CD11c- 
MHCII- CD115+ Flt3+ CD117low cells from BM cells of unmanipulated C57BL/6 mice 
were cocultured with total BM feeder cells and Flt3L for 4 days and the phenotype of 
their progeny was characterized. As expected, both pDCs and cDCs were generated 
from the CDPs. Within the CD11c+ BST2+ Siglec-H+ pDC population approximately 
70 % were CCR9- MHCIIlow consistent with the described phenotype of CCR9- pDC-
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like precursors, whereas approximately 30 % were CCR9+ MHCII+ consistent with a 
differentiated pDC phenotype (figure 7a). Thus, CDPs are efficient in generating 
CCR9- pDC-like precursors.  
 
The potential of CDPs to give rise to CCR9- pDC-like precursors was also tested in 
vivo by adoptive transfer into unirradiated C57BL/6 mice. Within the CD11c+ BST2+ 
Siglec-H+ pDC population derived from transferred CDPs after 5 days, CCR9- pDC-
like precursors were detected in BM and spleen at a higher frequency within the pDC 
population than was usually found within endogenous pDCs in these organs (figure 
7b, compare to figure 3b). In contrast, 7 days after transfer the frequency of CCR9- 
cells within the CDP-derived pDC population was very low in the BM and below 
detection in the spleen, suggesting further differentiation of CDP-derived CCR9- 
pDC-like precursors at later time points (figure 7c). Thus, CDPs can generate CCR9- 
pDC-like precursors in vitro and in vivo. These newly identified precursors have 
already partially activated the genetic program of the pDC lineage and are therefore 
biased to differentiate into pDC especially in BM and liver but can still contribute to 
the cDC pool in peripheral lymphoid and non-lymphoid tissues in the steady state. 
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Discussion 
In this study we demonstrate the existence of a novel DC precursor population 
positioned between the common DC progenitor and peripheral DC subpopulations 
which is distinct from pre-cDCs. This novel pDC-like DC precursor is efficient in 
generating pDCs but also makes a significant contribution to the cDC pool in the 
steady state. CCR9- pDC-like DC precursors are found at similar frequencies as pre-
cDCs not only in BM but also in peripheral lymphoid and non-lymphoid organs where 
differentiation into pDCs and cDCs is completed. These results demonstrate that final 
differentiation of pDCs is not restricted to the BM but can occur in peripheral tissues. 
We provide evidence that the local tissue microenvironment determines the 
developmental fate of these novel precursors with a preference of BM and liver to 
promote differentiation into pDCs while other lymphoid and non-lymphoid organs 
favor the generation of cDC subsets from these precursors. This explains how 
composition of the DC compartment of functionally distinct pDC and cDC 
subpopulations can be regulated in different organs and adapted to site-specific 
requirements. 
 
Gene expression profiling revealed that CCR9- pDC-like cells in murine BM bear a 
progenitor/precursor type signature, which is not found in the CCR9+ pDCs. This 
newly identified precursor population expresses simultaneously pDC-specific genes 
and genes involved in progenitor/precursor function which are also found in CDPs. 
The low expression of genes involved in antigen presentation and interaction with 
adaptive immunity further reveals that these cells are not fully differentiated pDCs but 
rather precursors. Many of the genes specific for the pDC-lineage including 
transcription factors E2-2 and SpiB are expressed at similar levels in both 
populations demonstrating affiliation with the pDC lineage. CCR9+ BM pDCs are 
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however more closely related to differentiated pDCs in secondary lymphoid organs 
and express many genes involved DC function at higher levels than CCR9- pDC-like 
cells. 
 
Since the newly identifed precursor population is CD11c+ MHCIIlow and is for the 
most part Lineage-positive due to expression of B220 and Ly-6C 19, it does not 
contain previously described CDPs 14,15,17 and does not significantly overlap with pre-
cDCs  which are Lin- CD11c+ MHCII- CD135+ 17. In previous seminal studies defining 
DC progenitors and precursors 6,14,15,17 the common DC precursor population 
described here was excluded by restricting the analysis and isolation to Lin- MHCII- 
cells. CCR9- pDC-like precursors are also functionally distinct from pre-cDCs in that 
they are biased to give rise to pDCs while pre-cDCs are mostly restricted to cDC 
generation 17. CCR9+ pDCs were the prevailing population among early descendants 
of CCR9- pDC-like precursors in all organs examined. In BM and liver CCR9+ pDCs 
were generated almost exclusively and maintained for at least 7 days. Also in other 
organs a sizable population of pDC progeny larger than that reported for pre-cDC 
descendants was found although cDCs dominated on day 7 after transfer in spleen 
and lung. 
 
The majority of cDC progeny derived from CCR9- pDC-like precursors in the spleen 
was CD8α- CD11b+, but a smaller population of CD8α+ CD11b- cDCs was also 
found. In the lung however only CD103- CD11b+ cDCs but not the CD103+ CD11b- 
equivalents of splenic CD8α+ cDCs were found. It is possible therefore that the 
CD8α+ cDC progeny found in spleen after 7 days are similar to a recently identified 
subpopulation of CD8α+ CX3CR1+ DCs, which is more closely related to the pDC 
lineage than the classical crosspresenting CD8α+ cDC population 32.  
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In comparison to CCR9- pDC-like precursors CCR9+ pDCs are mostly stable in their 
phenotype after transfer into mice in the steady state. The transcription factor E2-2 
which is critical for pDC development 27 actively maintains pDCs by inducing the 
transcriptional repressor Bcl11a and repressing the E2-2 inhibitor Id2 35. Deletion of 
E2-2 in differentiated pDCs leads to acquisition of a cDC-like phenotype similar but 
not identical to that of BST2low cells derived from CCR9- pDC-like precursors 48 
hours after transfer in our study 35. We have previously shown that diversion of 
CCR9- pDC-like cells from the pDC developmental pathway in response to epithelial 
cell derived factors in vitro is accompanied by downregulation of E2-2 and E2-2 
target gene expression and upregulation of Id2, whereas E2-2 expression in CCR9+ 
pDCs remains stable under these conditions 19. Our results obtained from the 
adoptive transfer studies confirm the assumption that CCR9+ pDCs have only low 
potential to give rise to cDCs in the steady state, while CCR9- pDC-like cells are still 
highly flexible. Thus, stable high level expression of E2-2 and a high E2-2/Id2 ratio 
appear to be required for stability of the pDC phenotype and function in CCR9+ pDCs 
in the steady state. It is currently unknown how expression, stability and activity of 
E2-2 and Id2 are regulated during development of pDCs. Expression of E2-2 above a 
certain treshhold may activate an autoregulatory loop which maintains E2-2 
expression and pDC cell fate as was shown for other transcription factors 36. In 
addition, E2-2 expression may be stabilized by epigenetic modification.  
 
It is striking that the frequency of pDCs within the DC compartment greatly differs 
between various tissues with high numbers in BM and liver but lower numbers in 
secondary lymphoid organs and even lower frequency in mucosal tissues. This could 
be due to differential recruitment or maintenance of pDCs at these sites, but also to 
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differentiation from a local progenitor with plasticity for pDC or cDC generation in 
response to cues from the microenvironment. In our study, we show that CCR9- 
pDC-like precursors are present in blood as well as peripheral lymphoid and non-
lymphoid tissues. Upon adoptive transfer CCR9- pDC-like precursors home to 
peripheral organs. The observation that CCR9- pDC-like precursors are derived from 
CDPs which are only found in BM in the steady state 17 further supports the 
interpretation that these cells are migratory DC precursors which can differentiate in 
the tissues. In addition, CCR9- pDC-like precursors preferentially give rise to CCR9+ 
pDCs in BM making it unlikely that cDCs first differentiate in the BM and then migrate 
to the tissues. It is possible however that pDCs differentiated from transferred CCR9- 
pDC-like precursors in the BM contribute to the pDC progeny found in the tissues at 
later time points.  
 
Our study demonstrates that the tissue microenvironment determines the 
developmental fate of CCR9- pDC-like precursors. Apparently these precursors find a 
specific niche in BM and liver which is conducive to pDC development and 
differentiation. It is currently unclear which factors within this niche support pDC 
differentiation or prevent cDC differentiation in these organs. Flt3L and M-CSF have 
been shown to promote pDC generation from precursors in vitro and in vivo 37-40 and 
specific local concentrations of these factors might favor pDC over cDC 
differentiation. Furthermore IFN-α was shown to promote pDC generation via STAT1-
mediated IRF8 induction 41. On the other hand, secondary lymphoid organs and 
mucosal tissues provide the microenvironment necessary for cDC differentiation.  We 
have previously shown that GM-CSF can induce differentiation of CCR9- pDC-like 
precursors into cDC-like cells in vitro, and it was shown that GM-CSF prevents 
development of pDC from early progenitors by STAT5-mediated inhibition of IRF8 
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expression 42. However, GM-CSF receptor signaling did not prove to be the essential 
factor for driving cDC differentiation in vivo in the steady state. It is likely that a 
combination of soluble and cell-bound factors within a hypothetical “DC niche” in 
these organs regulates the expression and activity of transcription factors which 
make the final cell fate decision for differentiation into pDC or cDC subpopulations. 
 
Our study defines successive developmental steps from the CDP to CCR9- pDC-like 
precursors and further on to differentiated pDC and cDC subpopulations. The data 
presented here is consistent with a model in which CDPs give rise to several types of 
precursors which are already partially committed to specific DC subpopulations. 
These migrate via the blood to different organs and their final differentiation is 
governed by microenvironmental factors in the individual “DC niches” of these 
tissues. High flexibility during the final stages of DC development allows adaptation 
to tissue-specific and situational requirements.
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Figure legends 
Figure 1 Global gene expression analysis in primary CCR9- and CCR9+ pDCs 
isolated from murine bone marrow 
Gene expression profiles of CCR9+ and CCR9- pDCs from murine BM were analyzed 
by microarray and compared to signature gene sets generated from the Immgen 
database. Pairwise comparison of mean signal intensities of all genes of the CCR9- 
and CCR9+ pDC subsets is shown (a). Expression of CDP-specific genes (b) and 
pDC-specific genes (c) was compared in CCR9- and CCR9+ pDC subsets. Genes 
overexpressed >2-fold in CCR9- pDCs are shown in red, genes overexpressed >2-
fold in CCR9+ pDCs are indicated in green. Selected genes are highlighted by a blue 
circle. The percentage of differentially regulated genes among total genes is 
indicated.  
 
Figure 2 Proliferation and morphology of CCR9- pDC-like precursors in bone 
marrow and spleen 
Expression of CD11c and the genetically encoded green-fluorescent cell cycle 
indicator (mAG-hGeminin) was analysed in primary Siglec-H+ BST2+ PI- cells from 
BM and spleen by flow cytometry. Fucci-transgenic mice expressing mAG-hGeminin 
were used and compared with WT control mice (a). Morphology of CCR9- pDC-like 
precursors and CCR9+ pDCs isolated from BM was assessed on cytospin samples 
with a 100x magnification oil immersion objective (b). 
 
Figure 3 CCR9- pDC-like precursors are found in and home to lymphoid as well 
as non-lymphoid organs  
The percentage of Siglec-H+ BST2+ PI- pDCs in the CD11c+ fraction (a), the 
percentage of CCR9- pDC-like precursors in Siglec-H+ BST2+ CD11cint PI- pDC 
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fraction (b) and the frequency of CCR9- pDC like precursors in total PI- lymphocytes 
(c) in BM, spleen, lymph nodes, Peyer’s patches, lung, liver and blood in steady state 
mice was determined by flow cytometry (mean ± SD, n=4). The recovery of Violet 
trace+ CD11c+ cells after i.v. transfer of CCR9- pDC-like precursors (open circles) or 
CCR9+ pDCs (black squares) was assessed 48h after transfer in BM, spleen, lymph 
nodes and Peyer’s patches (d), in liver (e) as well as in lung, small intestine, colon 
and blood (f). (d-f) Grey lines indicate mean values (n=4, Peyer’s patches * p = 0.02, 
lung * p = 0.003, colon * p = 0.03, Student’s t test). 
 
Figure 4 Transferred CCR9- pDC-like cells rapidly downregulate BST2 in a 
tissue dependent manner 
BST2 expression in Violet trace+ CD11c+ transferred CCR9- pDC-like precursors 
(open circles) or CCR9+ pDCs (black squares) was analyzed by flow cytometry 48h 
after transfer in BM, spleen, lymph nodes and Peyer’s patches (a) as well as liver, 
lung and small intestine (b). Grey lines indicate mean values (n=4, spleen * p = 0.02, 
lymph nodes * p = 0.01, Peyer’s patches * p = 0.02, Student’s t test). 
 
Figure 5 CCR9- pDC-like precursors aquire a cDC-like phenotype 48 hours after 
transfer 
Analysis of BST2 and CD11c expression in Violet trace+ cells in spleen, lymph nodes 
and Peyer’s patches 48h after transfer of CCR9- pDC-like precursors by flow 
cytometry (dot blots on the left, numbers indicate percentages of BST2high and 
BST2low cells). Analysis of Siglec-H, CCR9, MHC II and CD11b expression (right 
panel, histograms) in the BST2high and BST2low fractions of Violet trace+ CD11c+ cells 
48h after transfer of CCR9- pDC-like precursors in spleen, lymph nodes and Peyer’s 
patches (open histograms). Filled histograms: unstained control. Numbers in 
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histograms indicate mean fluorescence intensity (MFI). Results of one representative 
of 3 experiments are shown. 
 
Figure 6 Tissue specific generation of pDCs or cDC subpopulations on day 7 
after transfer 
CD45.2+ CCR9- pDC-like precursors were transferred into CD45.1+ steady state mice 
i.v. and progeny were analysed 7 days later by flow cytometry for the expression of 
BST2, CD11b, CD8α and CD103 in BM, spleen, lung and liver. Results of one 
representative of 3 experiments are shown (a). The percentages of BST2+ pDCs and 
BST2- cDCs within CD45.2+ CD11c+ MHC II+ PI- cells derived from transferred CCR9- 
pDC-like precursors after 7 days in BM, spleen, lung and liver (mean ± SD, n=3) (b). 
cDC subset compositions (CD8α+ CD11b- cDCs, CD8α- CD11b+ cDCs and double 
negative cDCs) in spleen and lung originating from CD45.2+ CCR9- pDC-like 
precursors 7 days after transfer are depicted (mean, n=3) (c). 
 
Figure 7 CDPs give rise to CCR9- pDC-like precursors 
CD45.2+ CDPs were cultured for 4 days with total CD45.1+ BM cells in medium 
supplemented with Flt3L and analysed for the expression of Siglec-H, CD11c, BST2, 
CCR9 and MHC II by flow cytometry (representative results of 4 replicates are 
shown) (a). CD45.2+ CDPs were transferred i.v. into CD45.1+ mice and the 
expression of Siglec-H, CD11c, BST2 and CCR9 on PI- CD45.2+ progeny was 
analysed after 5 days in BM and spleen by flow cytometry (results of one 
representative of 3 transfers are shown) (b). CD45.2+ CDPs were transferred i.v. into 
CD45.1+ mice and the expression of BST2 and CCR9 on PI- CD45.2+ Siglec-H+ 
progeny was analysed 7 days later in BM and spleen by flow cytometry (results of 
one representative of 6 transfers are shown) (c). 
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Figure 5 
CCR9- pDC-like precursor transfer 
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